Organoid-Based Precision Medicine Study to Test Chemotherapy Sensitivity in Osteosarcoma Patients

What this Trial Is About

Researchers are investigating how osteosarcoma, a type of bone cancer, responds to various chemotherapy drugs by testing tumor tissue in the laboratory. This study aims to see if tissue samples obtained during routine biopsies or surgeries can help predict which treatments might work best. Additional genetic testing of the tumor will also be done to improve understanding of osteosarcoma. The study uses a miniaturized system to grow tumor cells from patient samples in small ring-shaped cultures called organoids. These organoids mimic the original tumors characteristics and are tested with different drug treatments to measure how sensitive they are. The process includes seeding cells, growing organoids for 2-3 days, and then applying drug treatments over two days. Researchers have tested this method on over 120 sarcoma samples, including localized and metastatic osteosarcoma. Participants will undergo standard biopsies or surgeries to collect tumor tissue, which will be used to create organoids for testing. Researchers will monitor drug responses by measuring cell viability in these organoids. The study will track outcomes such as organoid growth, drug sensitivity, tumor necrosis, and clinical benefit over two years. This information may help guide better treatment choices for osteosarcoma patients.

An Organoid-based Functional Precision Medicine Trial in Osteosarcoma